back insurance patient resources covid-19 response request records first visit info common clinical fees billing inquiries pay bill

Practice Locations

UCHealth Lung Cancer Clinic - Anschutz Medical Campus
1665 Aurora Ct Anschutz Cancer Pavilion, Aurora, CO 80045

720-848-0300

Tejas Patil, MD

Hematology and Oncology

Board Certified

Schedule Appointment

Locations

Practice Locations

UCHealth Lung Cancer Clinic - Anschutz Medical Campus
1665 Aurora Ct Anschutz Cancer Pavilion, Aurora, CO 80045

720-848-0300

University of Colorado Cancer Center
CU Anschutz Medical Campus
1665 Aurora Ct Aurora, CO 80045

720-848-0300

Provider Expertise

Clinical Interest for Patients

My clinical and research interests include a focus on precision oncology in the management of patients with lung cancers. I am particularly interested in novel biomarker development, management of patients with oncogene driven cancer (such as ALK, ROS1, EGFR, MET, etc.), development of targeted therapies, and understanding mechanisms of acquired resistance.


Care Philosophy

I believe that there is no "one-size fits all" approach in medicine, especially with cancer therapy. I strive to use the best scientific principles available and tailor these to the individual needs and circumstances of each patient.


Specialties

  • Hematology and Oncology ( 2020 )
  • Internal Medicine ( 2016 )

Conditions & Treatments

  • Cancers

    Cancer Medicine, Lung Cancer

Interests & Activities

Personal Interests

I am interested in targeted therapies and novel biomarkers. My true passion outside of medicine is classical piano performance. I also dabble with sketch comedy, film, and skiing on the side.


Education & Training

Medical Schools

MD, Keck School of Medicine of the University of Southern California (2013)


Undergraduate Schools

BA, University of Pennsylvania (Philadelphia, PA) (2007)


Internships

University of Colorado (2013)


Residency Program

University of Colorado (2016)


Fellowships

University of Colorado (2020)

Professional Memberships

American Association of Cancer Research (AACR), Member


American Society of Clinical Oncology (ASCO), Member


European Society for Clinical Oncology (ESMO), Member


International Association for the Study of Lung Cancer (IASLC), Member


National Comprehensive Cancer Network (NCCN), NSCLC, Mesothelioma, Thymic Cancers - Committee Member


Rocky Mountain Oncology Society, President Elect


SWOG Cancer Research Network, Lung Steering Committee


Research & Grants

Grants

Patterns of relapse in stage III NSCLC treated with curative intent and the utility of serum tumors markers in the surveillance setting (2019)

Personalized medicine models and linked electronic database to assess racial and socioeconomic disparities among patients with lung cancer in Colorado (2020)

Programmed death ligand 1 (PD-L1) expression as a biomarker for tyrosine kinase inhibitor (TKI) efficacy among patients with ALK-rearranged NSCLC (2022)

MET and EGFR as biomarkers for amivantamab in overcoming RET TKI resistance (2022)


information for referring providers

Referral Contact Phone

720-848-0300

Clinical Interests for Referring Providers

My clinical and research interests include a focus on precision oncology in the management of patients with lung cancers. I am particularly interested in novel biomarker development, management of patients with oncogene driven cancer (such as ALK, ROS1, EGFR, BRAF, KRAS, RET, MET, HER2, etc.) and understanding mechanisms of acquired resistance.

Research Interest for Referring Providers

My research interests are primarily focused on developing a deeper understanding of prognostic and predictive biomarkers in lung cancer. My research initiatives at CU are focused in two areas: 1) leveraging molecular testing to identify prognostic and potentially predictive biomarkers to guide sequencing of anti-cancer therapies and 2), collaborating with basic science colleagues to develop novel in vitro and in vivo models to understand mechanisms of acquired resistance.